Structural analysis of the P132L disease mutation in caveolin-1 reveals its role in the assembly of oligomeric complexes

被引:5
|
作者
Han, Bing [1 ,2 ]
Gulsevin, Alican [3 ]
Connolly, Sarah [4 ]
Wang, Ting [1 ,2 ]
Meyer, Brigitte [2 ]
Porta, Jason [4 ]
Tiwari, Ajit [2 ]
Deng, Angie [5 ,8 ]
Chang, Louise [4 ]
Peskova, Yelena [1 ,2 ]
Mchaourab, Hassane S. [5 ]
Karakas, Erkan [5 ]
Ohi, Melanie D. [4 ,6 ]
Meiler, Jens [3 ,7 ]
Kenworthy, Anne K. [1 ,2 ]
机构
[1] Univ Virginia, Ctr Membrane & Cell Physiol, Charlottesville, VA 22904 USA
[2] Univ Virginia, Dept Mol Physiol & Biol Phys, Sch Med, Charlottesville, VA 22904 USA
[3] Vanderbilt Univ, Dept Chem, Nashville, TN USA
[4] Univ Michigan, Life Sci Inst, Ann Arbor, MI USA
[5] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN USA
[6] Univ Michigan, Dept Cell & Dev Biol, Sch Med, Ann Arbor, MI USA
[7] Univ Leipzig, Inst Drug Discovery, Leipzig, Germany
[8] Stanford Childrens Hosp, Palo Alto, CA USA
基金
美国国家卫生研究院;
关键词
MUSCULAR-DYSTROPHY LGMD-1C; GENE FAMILY; BREAST-CANCER; MEMBRANE; PROTEIN; EXPRESSION; INSIGHTS; BEHAVIOR; MUTANTS; IDENTIFICATION;
D O I
10.1016/j.jbc.2023.104574
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Caveolin-1 (CAV1) is a membrane-sculpting protein that oligomerizes to generate flask-shaped invaginations of the plasma membrane known as caveolae. Mutations in CAV1 have been linked to multiple diseases in humans. Such mutations often interfere with oligomerization and the intracellular trafficking processes required for successful caveolae assembly, but the molecular mechanisms underlying these defects have not been structurally explained. Here, we investigate how a disease-associated mutation in one of the most highly conserved residues in CAV1, P132L, affects CAV1 structure and oligomerization. We show that P132 is positioned at a major site of protomer-protomer interactions within the CAV1 complex, providing a structural explanation for why the mutant protein fails to homo-oligomerize correctly. Using a combination of computational, structural, biochemical, and cell biological approaches, we find that despite its homo-oligomerization defects P132L is capable of forming mixed hetero-oligomeric complexes with WT CAV1 and that these complexes can be incorporated into caveolae. These findings provide insights into the fundamental mechanisms that control the formation of homo-and hetero-oligomers of caveolins that are essential for caveolae biogenesis, as well as how these processes are disrupted in human disease.
引用
收藏
页数:18
相关论文
共 29 条
  • [1] Probing the Caveolin-1 P132L Mutant: Critical Insights into Its Oligomeric Behavior and Structure
    Rieth, Monica D.
    Lee, Jinwoo
    Glover, Kerney Jebrell
    BIOCHEMISTRY, 2012, 51 (18) : 3911 - 3918
  • [2] Caveolin-1 P132L Mutation in Human Cancers 1 CAVeat to be Voiced
    Lacroix-Triki, Magali
    Geyer, Felipe Correa
    Reis-Filho, Jorge Sergio
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2010, 12 (05): : 562 - 565
  • [3] Absence of the Caveolin-1 P132L Mutation in Cancers of the Breast and Other Organs
    Koike, Shinya
    Kodera, Yasuhiro
    Nakao, Akimasa
    Iwata, Hiroji
    Yatabe, Yasushi
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2010, 12 (05): : 712 - 717
  • [4] Lack of caveolin-1 (P132L) somatic mutations in breast cancer
    Ferraldeschi, Roberta
    Latif, Ayse
    Clarke, Robert B.
    Spence, Katherine
    Ashton, Garry
    O'Sullivan, James
    Evans, D. Gareth
    Howell, Anthony
    Newman, William G.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (03) : 1185 - 1186
  • [5] Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer - Caveolin-1 (P132L) behaves in a dominant-negative manner and Caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia
    Lee, H
    Park, DS
    Razani, B
    Russell, RG
    Pestell, RG
    Lisanti, MP
    AMERICAN JOURNAL OF PATHOLOGY, 2002, 161 (04): : 1357 - 1369
  • [6] Lack of caveolin-1 (P132L) somatic mutations in breast cancer
    Roberta Ferraldeschi
    Ayse Latif
    Robert B. Clarke
    Katherine Spence
    Garry Ashton
    James O’Sullivan
    D. Gareth Evans
    Anthony Howell
    William G. Newman
    Breast Cancer Research and Treatment, 2012, 132 : 1185 - 1186
  • [7] Using Caveolin-1 epithelial immunostaining patterns to stratify human breast cancer patients and predict the Caveolin-1 (P132L) mutation
    Mercier, Isabelle
    Bryant, Kelly G.
    Sotgia, Federica
    Bonuccelli, Gloria
    Witkiewicz, Agnieszka K.
    Dasgupta, Abhijit
    Jasmin, Jean-Francois
    Pestell, Richard G.
    Lisanti, Michael P.
    CELL CYCLE, 2009, 8 (09) : 1396 - 1401
  • [8] Caveolin-1 (P132L), a Common Breast Cancer Mutation, Confers Mammary Cell Invasiveness and Defines a Novel Stem Cell/Metastasis-Associated Gene Signature
    Bonuccelli, Gloria
    Casimiro, Mathew C.
    Sotgia, Federica
    Wang, Chenguang
    Liu, Manran
    Katiyar, Sanjay
    Zhou, Jie
    Dew, Elliott
    Capozza, Franco
    Daumer, Kristin M.
    Minetti, Carlo
    Milliman, Janet N.
    Alpy, Fabien
    Rio, Marie-Christine
    Tomasetto, Catherine
    Mercier, Isabelle
    Flomenberg, Neal
    Frank, Philippe G.
    Pestell, Richard G.
    Lisanti, Michael P.
    AMERICAN JOURNAL OF PATHOLOGY, 2009, 174 (05): : 1650 - 1662
  • [9] The caveolae targeting defect of the breast cancer-associated P132L mutant of caveolin-1 can be rescued by co-expression with wild type caveolin-1.
    Han, B.
    Tiwari, A.
    Kenworthy, A. K.
    MOLECULAR BIOLOGY OF THE CELL, 2015, 26
  • [10] Caveolin-1 mutants P132L and Y14F are dominant negative regulators of invasion, migration and aggregation in H1299 lung cancer cells
    Shatz, Maria
    Lustig, Gila
    Reich, Reuven
    Liscovitch, Mordechai
    EXPERIMENTAL CELL RESEARCH, 2010, 316 (10) : 1748 - 1762